2023 Q4 Form 10-K Financial Statement

#000141057824000198 Filed on March 14, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.385M $6.071M
YoY Change -5.95% -7.81%
% of Gross Profit
Research & Development $832.4K $3.308M
YoY Change 35.77% 23.76%
% of Gross Profit
Depreciation & Amortization $25.68K $103.7K
YoY Change -1.27% -0.32%
% of Gross Profit
Operating Expenses $2.218M $9.379M
YoY Change 6.32% 1.3%
Operating Profit
YoY Change
Interest Expense $167.8K $691.9K
YoY Change 97.47% -212.14%
% of Operating Profit
Other Income/Expense, Net $0.00 $691.9K
YoY Change -658.95%
Pretax Income -$2.050M -$8.687M
YoY Change 2.44% -7.41%
Income Tax
% Of Pretax Income
Net Earnings -$2.050M -$8.687M
YoY Change 2.44% -7.41%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.19 -$9.64
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.69M $10.69M
YoY Change -16.79% -16.79%
Cash & Equivalents $2.400M
Short-Term Investments $8.294M $8.294M
Other Short-Term Assets $591.0K $591.0K
YoY Change 14.41% 14.41%
Inventory
Prepaid Expenses $591.0K
Receivables
Other Receivables
Total Short-Term Assets $11.29M $11.29M
YoY Change -15.59% -15.59%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $583.3K
YoY Change -17.21%
Long-Term Investments
YoY Change
Other Assets $300.0K $300.0K
YoY Change -21.75% -21.75%
Total Long-Term Assets $883.3K $883.3K
YoY Change -18.81% -18.81%
TOTAL ASSETS
Total Short-Term Assets $11.29M $11.29M
Total Long-Term Assets $883.3K $883.3K
Total Assets $12.17M $12.17M
YoY Change -15.83% -15.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $526.5K $526.5K
YoY Change -13.06% -13.06%
Accrued Expenses $1.309M $2.455M
YoY Change 11.31% 5.73%
Deferred Revenue
YoY Change
Short-Term Debt $600.0K $600.0K
YoY Change 0.0% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.581M $3.581M
YoY Change 1.53% 1.53%
LONG-TERM LIABILITIES
Long-Term Debt $2.924M $2.924M
YoY Change -17.03% -17.03%
Other Long-Term Liabilities $2.924M
YoY Change -17.03%
Total Long-Term Liabilities $2.924M $2.924M
YoY Change -17.03% -17.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.581M $3.581M
Total Long-Term Liabilities $2.924M $2.924M
Total Liabilities $6.505M $6.505M
YoY Change -7.74% -7.74%
SHAREHOLDERS EQUITY
Retained Earnings -$46.20M
YoY Change 23.15%
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.664M $5.664M
YoY Change
Total Liabilities & Shareholders Equity $12.17M $12.17M
YoY Change -15.83% -15.83%

Cashflow Statement

Concept 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$2.050M -$8.687M
YoY Change 2.44% -7.41%
Depreciation, Depletion And Amortization $25.68K $103.7K
YoY Change -1.27% -0.32%
Cash From Operating Activities -$3.224M -$7.864M
YoY Change 65.97% -7.27%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $2.644M $2.188M
YoY Change -122.11%
Cash From Investing Activities $2.644M $2.188M
YoY Change -121.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -182.6K 5.217M
YoY Change -59.14% -62.76%
NET CHANGE
Cash From Operating Activities -3.224M -7.864M
Cash From Investing Activities 2.644M 2.188M
Cash From Financing Activities -182.6K 5.217M
Net Change In Cash -762.2K -459.4K
YoY Change -68.1% -90.06%
FREE CASH FLOW
Cash From Operating Activities -$3.224M -$7.864M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/srt/2023#OfficerMember
CY2023Q4 us-gaap Other Liability Noncurrent Related Party Type Extensible Enumeration
OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/srt/2023#OfficerMember
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Other Liability Related Party Type Extensible Enumeration
OtherLiabilityRelatedPartyTypeExtensibleEnumeration
http://fasb.org/srt/2023#OfficerMember
CY2023Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/srt/2023#OfficerMember
CY2023Q4 us-gaap Other Liability Noncurrent Related Party Type Extensible Enumeration
OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/srt/2023#OfficerMember
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001671502
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Registrant Name
EntityRegistrantName
Quoin Pharmaceuticals, Ltd.
CY2022Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/srt/2023#OfficerMember
CY2022Q4 us-gaap Other Liability Noncurrent Related Party Type Extensible Enumeration
OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/srt/2023#OfficerMember
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
987220
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
403887
CY2023Q3 qnrx Shares Owned Percentage
SharesOwnedPercentage
0.00083
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.67
CY2023 us-gaap Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense
CY2022Q4 us-gaap Other Liability Related Party Type Extensible Enumeration
OtherLiabilityRelatedPartyTypeExtensibleEnumeration
http://fasb.org/srt/2023#OfficerMember
CY2022Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/srt/2023#OfficerMember
CY2022Q4 us-gaap Other Liability Noncurrent Related Party Type Extensible Enumeration
OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/srt/2023#OfficerMember
CY2023Q3 qnrx Shares Owned Percentage
SharesOwnedPercentage
0.00083
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37846
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L3
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
92-2593104
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
42127 Pleasant Forest Court
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Ashburn
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20148
CY2023 dei City Area Code
CityAreaCode
703
CY2023 dei Local Phone Number
LocalPhoneNumber
980-4182
CY2023 dei Security12b Title
Security12bTitle
American Depositary Shares
CY2023 dei Trading Symbol
TradingSymbol
QNRX
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
5800000
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 dei Auditor Name
AuditorName
Marcum LLP
CY2023 dei Auditor Firm
AuditorFirmId
688
CY2023 dei Auditor Location
AuditorLocation
East Hanover, New Jersey
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2401198
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2860628
CY2023Q4 us-gaap Investments
Investments
8293663
CY2022Q4 us-gaap Investments
Investments
9992900
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
591034
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
516584
CY2023Q4 us-gaap Assets Current
AssetsCurrent
11285895
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13370112
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
300000
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
383390
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
583334
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
704561
CY2023Q4 us-gaap Assets
Assets
12169229
CY2022Q4 us-gaap Assets
Assets
14458063
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
526523
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
605600
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1308706
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1175705
CY2023Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
1146251
CY2022Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
1146251
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
600000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
600000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3581480
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3527556
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2923733
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3523733
CY2023Q4 us-gaap Liabilities
Liabilities
6505213
CY2022Q4 us-gaap Liabilities
Liabilities
7051289
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
8333334
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
987220
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
403887
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2023 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
0
CY2022 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
45
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
2932000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
51867336
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47855521
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46203320
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-37516747
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5664016
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7406774
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12169229
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14458063
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6070517
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6584868
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3307987
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2672836
CY2023 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9378504
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9257704
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
416000
CY2022 qnrx Warrant Liability Income Expense Value
WarrantLiabilityIncomeExpenseValue
-77237
CY2023 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-2683
CY2022 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1307
CY2023 qnrx Realized And Accrued Interest Income
RealizedAndAccruedInterestIncome
694614
CY2022 qnrx Realized And Accrued Interest Income
RealizedAndAccruedInterestIncome
95745
CY2022 qnrx Increase In Accrued Interest And Financing Expenses
IncreaseInAccruedInterestAndFinancingExpenses
714081
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
691931
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-123792
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8686573
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-9381496
CY2022 qnrx Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
65266
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8686573
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9446762
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
657032
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-9381496
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
764007
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14877332
CY2022 qnrx Stock Issued During Period Value Settlement Of Accrued Liabilities
StockIssuedDuringPeriodValueSettlementOfAccruedLiabilities
193537
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
296362
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7406774
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8686573
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1094549
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5849266
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5664016
CY2023 us-gaap Profit Loss
ProfitLoss
-8686573
CY2022 us-gaap Profit Loss
ProfitLoss
-9381496
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-77237
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1094549
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
764007
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
416000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
103706
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
104043
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
17521
CY2022 qnrx Increase In Accrued Interest And Financing Expenses
IncreaseInAccruedInterestAndFinancingExpenses
714081
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
489079
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
93779
CY2023 qnrx Increase Decrease In Accounts Payable And Accrued Expenses
IncreaseDecreaseInAccountsPayableAndAccruedExpenses
53924
CY2022 qnrx Increase Decrease In Accounts Payable And Accrued Expenses
IncreaseDecreaseInAccountsPayableAndAccruedExpenses
-217806
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-41523
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-123455
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7864429
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8480732
CY2023 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
18090684
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
9899121
CY2023 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
20279000
CY2022 qnrx Payments For Previous Intangible Asset Acquisition
PaymentsForPreviousIntangibleAssetAcquisition
250000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2188316
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10149121
CY2023 qnrx Payments For Proceeds From Deferred Loan Costs
PaymentsForProceedsFromDeferredLoanCosts
32583
CY2022 qnrx Payments For Proceeds From Deferred Loan Costs
PaymentsForProceedsFromDeferredLoanCosts
-42045
CY2023 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
600000
CY2022 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
599999
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
311670
CY2023 qnrx Net Proceeds From Issuance Of Common Stock
NetProceedsFromIssuanceOfCommonStock
5849266
CY2022 qnrx Net Proceeds From Issuance Of Common Stock
NetProceedsFromIssuanceOfCommonStock
14877332
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5216683
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14007708
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-459430
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4622145
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2860628
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7482773
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2401198
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2860628
CY2022 qnrx Reclassification Of Warrant Liability To Equity Upon Issuance Of Exchange Warrants
ReclassificationOfWarrantLiabilityToEquityUponIssuanceOfExchangeWarrants
296362
CY2022 qnrx Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
65266
CY2023 qnrx Offering Expenses Associated With Warrant Modification
OfferingExpensesAssociatedWithWarrantModification
238231
CY2022 qnrx Offering Expenses Associated With Warrant Modification
OfferingExpensesAssociatedWithWarrantModification
491601
CY2022 qnrx Settlement Of Accrued Liabilities
SettlementOfAccruedLiabilities
193537
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
46200000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2400000
CY2023Q4 us-gaap Investments
Investments
8300000
CY2023Q3 qnrx Number Of Shares Represented For One American Depositary Share
NumberOfSharesRepresentedForOneAmericanDepositaryShare
60000
CY2023Q4 qnrx Number Of Ordinary Shares For American Depositary Shares
NumberOfOrdinarySharesForAmericanDepositaryShares
60000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: settlement of debt or other obligations, stock-based compensation, research and development expense recognition, intangible asset estimated useful lives and impairment assessments, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations.</p>
CY2023Q4 us-gaap Trading Securities
TradingSecurities
8300000
CY2022Q4 us-gaap Trading Securities
TradingSecurities
10000000.0
CY2023 qnrx Investmentsmaturityterm
Investmentsmaturityterm
P4M
CY2023Q4 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2023 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
1
CY2022 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
32583
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
401972
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
508084
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
8500
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
8500
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
12000000.0
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
33333
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
491000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.106
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.060
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.048
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.027
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y4M24D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
6.62
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
210.00
CY2023 qnrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value Of American Depositary Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAmericanDepositaryShare
4.31
CY2022 qnrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value Of American Depositary Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAmericanDepositaryShare
184.56
CY2023 qnrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Estimated Fair Value Of Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsEstimatedFairValueOfOption
3.60
CY2022 qnrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Estimated Fair Value Of Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsEstimatedFairValueOfOption
155.04
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1090000.00
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
764000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3.0
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y8M12D
CY2023Q4 qnrx Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
447979
CY2022Q4 qnrx Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
383390
CY2023Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
891034
CY2022Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
899974
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
591034
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
516584
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
300000
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
383390
CY2023Q4 qnrx Accrued Research Contract Expense Current
AccruedResearchContractExpenseCurrent
358287
CY2022Q4 qnrx Accrued Research Contract Expense Current
AccruedResearchContractExpenseCurrent
105071
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
804156
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
788169
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
93989
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
159593
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
50534
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
44278
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1740
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
78594
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1308706
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1175705
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3523733
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1000000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1040433
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
416666
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
335872
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
583334
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
704561
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
104000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
104000
CY2023 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
18000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
100000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
100000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
100000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
100000
CY2023Q4 qnrx Finite Lived Intangible Assets Amortization After Year Four
FiniteLivedIntangibleAssetsAmortizationAfterYearFour
183000
CY2023Q4 us-gaap Other Liabilities
OtherLiabilities
3523733
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
4123732
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
600000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
600000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2923733
CY2022Q3 qnrx Shares Owned Percentage
SharesOwnedPercentage
0.125
CY2023Q4 qnrx Number Of Ordinary Shares For American Depositary Shares
NumberOfOrdinarySharesForAmericanDepositaryShares
500000000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q4 qnrx Number Of Ordinary Shares For American Depositary Shares
NumberOfOrdinarySharesForAmericanDepositaryShares
6000000000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Treasury Stock Shares Retired
TreasuryStockSharesRetired
45
CY2023Q4 qnrx Number Of Years Income For Distribution Limit
NumberOfYearsIncomeForDistributionLimit
2
CY2023 qnrx Date Of Financial Statements And Distribution Period Maximum
DateOfFinancialStatementsAndDistributionPeriodMaximum
P6M
CY2023Q4 qnrx Number Of Years Income For Distribution Limit
NumberOfYearsIncomeForDistributionLimit
2
CY2022Q3 qnrx Stock Issued During Period Shares Settlement Of Accrued Liabilities
StockIssuedDuringPeriodSharesSettlementOfAccruedLiabilities
3682
CY2023Q1 qnrx Aggregate Gross Proceeds From Issuance Offering
AggregateGrossProceedsFromIssuanceOffering
7000000.0
CY2023Q1 qnrx Net Proceeds From Issuance Offering
NetProceedsFromIssuanceOffering
5800000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
664.68
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
597.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
64.20
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.13
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4276000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3334000
CY2023Q4 qnrx Deferred Tax Assets Tax Deferred Expense Accrued Expenses And Other
DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther
175000
CY2022Q4 qnrx Deferred Tax Assets Tax Deferred Expense Accrued Expenses And Other
DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther
189000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
321000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
76000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
289000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
178000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1104000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
581000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
51000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
34000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6216000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4392000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6216000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4392000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1824000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1970000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
167000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
153000
CY2023 qnrx Effective Income Tax Rate Reconciliation Research And Development Amount
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentAmount
-195000
CY2022 qnrx Effective Income Tax Rate Reconciliation Research And Development Amount
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentAmount
-76000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
79000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
388000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1824000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
347000
CY2023 qnrx Effective Income Tax Rate Reconciliation Deferred True Up Amount
EffectiveIncomeTaxRateReconciliationDeferredTrueUpAmount
-51000
CY2022 qnrx Effective Income Tax Rate Reconciliation Deferred True Up Amount
EffectiveIncomeTaxRateReconciliationDeferredTrueUpAmount
1158000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6216000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4392000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 qnrx Deferred Tax Asset Capitalization Of Research And Development Costs
DeferredTaxAssetCapitalizationOfResearchAndDevelopmentCosts
4617000
CY2023 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">NOTE 16 - CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, the Company may become involved in various legal matters arising in the ordinary course of business. Management is unaware of any matters requiring accrual for related losses in the financial statements.</p>
CY2023 qnrx Number Of License And Supply Agreements Entered
NumberOfLicenseAndSupplyAgreementsEntered
9
CY2022 qnrx Number Of License And Supply Agreements Entered
NumberOfLicenseAndSupplyAgreementsEntered
8
CY2023 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
0

Files In Submission

Name View Source Status
0001410578-24-000198-index-headers.html Edgar Link pending
0001410578-24-000198-index.html Edgar Link pending
0001410578-24-000198.txt Edgar Link pending
0001410578-24-000198-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
qnrx-20231231.xsd Edgar Link pending
qnrx-20231231x10k.htm Edgar Link pending
qnrx-20231231xex23d1.htm Edgar Link pending
qnrx-20231231xex31d1.htm Edgar Link pending
qnrx-20231231xex31d2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
qnrx-20231231x10k_htm.xml Edgar Link completed
qnrx-20231231xex32d1.htm Edgar Link pending
qnrx-20231231xex32d2.htm Edgar Link pending
qnrx-20231231xex4d19.htm Edgar Link pending
qnrx-20231231xex97d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
qnrx-20231231_pre.xml Edgar Link unprocessable
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
qnrx-20231231_def.xml Edgar Link unprocessable
qnrx-20231231_cal.xml Edgar Link unprocessable
qnrx-20231231_lab.xml Edgar Link unprocessable